Literature DB >> 16940241

Clinical and functional characterization of a human ORNT1 mutation (T32R) in the hyperornithinemia-hyperammonemia-homocitrullinuria (HHH) syndrome.

José A Camacho1, Rebecca Mardach, Natalia Rioseco-Camacho, Eduardo Ruiz-Pesini, Olga Derbeneva, Dario Andrade, Frank Zaldivar, Yong Qu, Stephen D Cederbaum.   

Abstract

We studied two related families (HHH013 and HHH015) with the hyperornithinemia-hyperammonemia-homocitrullinuria (HHH) syndrome, a disorder of the urea cycle and ornithine degradation pathway, who have the same novel ornithine transporter (ORNT1) genotype (T32R) but a variable phenotype. Both HHH015 patients are doing well in school and are clinically stable; conversely, the three affected HHH013 siblings had academic difficulties and one suffered recurrent episodes of hyperammonemia and ultimately died. Overexpression studies revealed that the product of the ORNT1-T32R allele has residual function. Ornithine transport studies in HHH015 fibroblasts, however, showed basal activity similar to fibroblasts carrying nonfunctional ORNT1 alleles. We also examined two potential modifying factors, the ORNT2 gene and the mitochondrial DNA lineage (haplogroup). Haplogroups, associated with specific diseases, are hypothesized to influence mitochondrial function. Results demonstrated that both HHH015 patients are heterozygous for an ORNT2 gain of function polymorphism and belong to haplogroup A whereas the HHH013 siblings carry the wild-type ORNT2 and are haplogroup H. These observations suggest that the ORNT1 genotype cannot predict the phenotype of HHH patients. The reason for the phenotypic variability is unknown, but factors such as redundant transporters and mitochondrial lineage may contribute to the neuropathophysiology of HHH patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16940241     DOI: 10.1203/01.pdr.0000238301.25938.f5

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  7 in total

Review 1.  Physiological and pathological roles of mitochondrial SLC25 carriers.

Authors:  Manuel Gutiérrez-Aguilar; Christopher P Baines
Journal:  Biochem J       Date:  2013-09-15       Impact factor: 3.857

2.  Adult-onset presentation of a hyperornithinemia-hyperammonemia-homocitrullinuria patient without prior history of neurological complications.

Authors:  Kamer Tezcan; Kristal T Louie; Yong Qu; Jorge Velasquez; Frank Zaldivar; Natalia Rioseco-Camacho; José Angel Camacho
Journal:  JIMD Rep       Date:  2011-09-22

3.  Diagnosis and high incidence of hyperornithinemia-hyperammonemia-homocitrullinemia (HHH) syndrome in northern Saskatchewan.

Authors:  AbdulRazaq A H Sokoro; Joyce Lepage; Nick Antonishyn; Ryan McDonald; Cheryl Rockman-Greenberg; James Irvine; Denis C Lehotay
Journal:  J Inherit Metab Dis       Date:  2010-06-24       Impact factor: 4.982

Review 4.  The hyperornithinemia-hyperammonemia-homocitrullinuria syndrome.

Authors:  Diego Martinelli; Daria Diodato; Emanuela Ponzi; Magnus Monné; Sara Boenzi; Enrico Bertini; Giuseppe Fiermonte; Carlo Dionisi-Vici
Journal:  Orphanet J Rare Dis       Date:  2015-03-11       Impact factor: 4.123

Review 5.  Diseases Caused by Mutations in Mitochondrial Carrier Genes SLC25: A Review.

Authors:  Ferdinando Palmieri; Pasquale Scarcia; Magnus Monné
Journal:  Biomolecules       Date:  2020-04-23

Review 6.  Organelle transporters and inter-organelle communication as drivers of metabolic regulation and cellular homeostasis.

Authors:  Aakriti Jain; Roberto Zoncu
Journal:  Mol Metab       Date:  2022-03-25       Impact factor: 8.568

7.  A novel mutation in the SLC25A15 gene in a Turkish patient with HHH syndrome: functional analysis of the mutant protein.

Authors:  Nagehan Ersoy Tunalı; Carlo M T Marobbio; N Ozan Tiryakioğlu; Giuseppe Punzi; Seha K Saygılı; Hasan Onal; Ferdinando Palmieri
Journal:  Mol Genet Metab       Date:  2014-03-20       Impact factor: 4.797

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.